{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T07:11:54Z","timestamp":1782371514100,"version":"3.54.5"},"reference-count":44,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Science and Technology Plan Project of Quanzhou City, Fujian Province, China","award":["2022N029S"],"award-info":[{"award-number":["2022N029S"]}]},{"name":"the Science and Technology Plan Project of Quanzhou City, Fujian Province, China","award":["XDHT 20233160A0125"],"award-info":[{"award-number":["XDHT 20233160A0125"]}]},{"name":"Anxi County Hospital, Quanzhou, Province, Chin","award":["2022N029S"],"award-info":[{"award-number":["2022N029S"]}]},{"name":"Anxi County Hospital, Quanzhou, Province, Chin","award":["XDHT 20233160A0125"],"award-info":[{"award-number":["XDHT 20233160A0125"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxics"],"abstract":"<jats:p>Thrombosis is a major health concern that contributes to the development of several cardiovascular diseases and a significant number of fatalities worldwide. While stent surgery is the current recommended treatment according to the guidelines, percutaneous coronary intervention (PCI) is the optimal approach for acute myocardial infarction (AMI). However, in remote areas with limited resources, PCI procedures may not be feasible, leading to a delay in treatment and irreversible outcomes. In such cases, preoperative thrombolysis becomes the primary choice for managing AMI in remote settings. The market for thrombolytic drugs is continuously evolving, and identifying a safe and effective thrombolytic agent for treating AMI is crucial. This study evaluated Urokinase, Alteplase, and Recombinant Human TNK Tissue-type Plasminogen Activator for Injection (rhTNK) as representatives of first-, second-, and third-generation thrombolytic drugs, respectively. The research included in vitro thrombolysis experiments, exposure of human cardiomyocytes, zebrafish tail vein injections, and vascular endothelial transgenic zebrafish models. The findings revealed that rhTNK is the most effective thrombolytic drug with the least adverse effects and lowest bleeding rate, highlighting its potential as the preferred treatment option for AMI. The order of thrombolytic effectiveness was Urokinase &lt; Alteplase &lt; rhTNK, with adverse effects on cardiomyocytes post-thrombolytic therapy ranking similarly as Urokinase &lt; Alteplase &lt; rhTNK, while the bleeding rate after thrombolysis followed the order of Urokinase &gt; Alteplase &gt; rhTNK.<\/jats:p>","DOI":"10.3390\/toxics12070458","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T09:29:33Z","timestamp":1719394173000},"page":"458","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparative Analysis of Therapeutic Efficacy and Adverse Reactions among Various Thrombolytic Agents"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2548-5293","authenticated-orcid":false,"given":"Chenxi","family":"Xie","sequence":"first","affiliation":[{"name":"Chest Pain Center, Anxi County Hospital, Quanzhou 362300, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naying","family":"Zheng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen 361005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingmei","family":"Li","sequence":"additional","affiliation":[{"name":"Chest Pain Center, Anxi County Hospital, Quanzhou 362300, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Chest Pain Center, Anxi County Hospital, Quanzhou 362300, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongqin","family":"Huang","sequence":"additional","affiliation":[{"name":"Chest Pain Center, Anxi County Hospital, Quanzhou 362300, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meizhu","family":"Xiao","sequence":"additional","affiliation":[{"name":"Chest Pain Center, Anxi County Hospital, Quanzhou 362300, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Chen","sequence":"additional","affiliation":[{"name":"Chest Pain Center, Anxi County Hospital, Quanzhou 362300, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyong","family":"He","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen 361005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6705-3033","authenticated-orcid":false,"given":"Zhenghong","family":"Zuo","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen 361005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintan","family":"Chen","sequence":"additional","affiliation":[{"name":"Chest Pain Center, Anxi County Hospital, Quanzhou 362300, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.jacc.2021.03.003","article-title":"The Edge of Time in Acute Myocardial Infarction","volume":"77","author":"Dauerman","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","unstructured":"Mechanic, O.J., Gavin, M., and Grossman, S.A. (2024). Acute Myocardial Infarction. StatPearls [Internet], StatPearls Publishing."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Rehman, S., Rehman, E., Ikram, M., and Jianglin, Z. (2021). Cardiovascular disease (CVD): Assessment, prediction and policy implications. BMC Public Health, 21.","DOI":"10.1186\/s12889-021-11334-2"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41569-018-0119-4","article-title":"Epidemiological Features of Cardiovascular Disease in Asia","volume":"16","author":"Zhao","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Access Investigators (2011). Management of acute coronary syndromes in developing countries: Acute Coronary Events\u2014A multinational Survey of current management Strategies. Am. Heart J., 162, 852\u2013859.e22.","DOI":"10.1016\/j.ahj.2011.07.029"},{"key":"ref_6","first-page":"27","article-title":"Global geographical variations in ST-segment elevation myocardial infarction management and post-discharge mortality","volume":"24","author":"Huo","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1001\/jamacardio.2019.0897","article-title":"CPACS-3 Investigators. Effect of a Quality of Care Improvement Initiative in Patients with Acute Coronary Syndrome in Resource-Constrained Hospitals in China: A Randomized Clinical Trial","volume":"4","author":"Wu","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(96)02514-7","article-title":"Early thrombolytic treatment in acute myocardial infarction: Reappraisal of the golden hour","volume":"348","author":"Boersma","year":"1996","journal-title":"Lancet"},{"key":"ref_9","first-page":"e52045","article-title":"Prehospital Fibrinolysis Therapy in Acute Myocardial Infarction: A Narrative Review","volume":"16","author":"Alsomali","year":"2024","journal-title":"Cureus"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.amjcard.2021.10.043","article-title":"Serum Albumin and Bleeding Events after Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction (from the HAGAKURE-ACS Registry)","volume":"165","author":"Yoshioka","year":"2022","journal-title":"Am. J. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.pcad.2017.05.002","article-title":"The Role for Cardiologists in Stroke Intervention","volume":"59","author":"Heuser","year":"2017","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11239-005-3546-0","article-title":"Combined thrombolysis with abciximab favourably influences platelet-leukocyte interactions and platelet activation in acute myocardial infarction","volume":"20","author":"Szabo","year":"2005","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1089-2516(01)90003-4","article-title":"Society of Cardiovascular and Interventional Radiology (SCVIR). Alteplase and tenecteplase: Applications in the peripheral circulation","volume":"4","author":"Semba","year":"2001","journal-title":"Tech. Vasc. Interv. Radiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/neurintsurg-2019-015489","article-title":"Mechanical behavior of in vitro blood clots and the implications for acute ischemic stroke treatment","volume":"12","author":"Johnson","year":"2020","journal-title":"J. Neurointerv. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1160\/TH08-02-0103","article-title":"Interspecies differences in coagulation profile","volume":"100","author":"Plasenzotti","year":"2008","journal-title":"Thromb. Haemost."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e842","DOI":"10.1002\/cpz1.842","article-title":"Immunofluorescence Microscopy","volume":"3","author":"Galati","year":"2023","journal-title":"Curr. Protoc."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/jbio.201500287","article-title":"Zebrafish model of photochemical thrombosis for translational research and thrombolytic screening in vivo","volume":"10","author":"Lee","year":"2017","journal-title":"J. Biophotonics"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jes.2020.07.019","article-title":"Comparison of developmental toxicity of different surface modified CdSe\/ZnS QDs in zebrafish embryos","volume":"100","author":"Zheng","year":"2021","journal-title":"J. Environ. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10571-019-00737-w","article-title":"Urokinase Plasminogen Activator: A Potential Thrombolytic Agent for Ischaemic Stroke","volume":"40","author":"Kadir","year":"2020","journal-title":"Cell Mol. Neurobiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1474-4422(17)30253-3","article-title":"Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): A phase 3, randomised, open-label, blinded endpoint trial","volume":"16","author":"Logallo","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s13311-023-01391-3","article-title":"Evolving Thrombolytics: From Alteplase to Tenecteplase","volume":"20","author":"Miller","year":"2023","journal-title":"Neurotherapeutics"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e016838","DOI":"10.1136\/bmjopen-2017-016838","article-title":"Recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA) versus alteplase (rt-PA) as fibrinolytic therapy for acute ST-segment elevation myocardial infarction (China TNK STEMI): Protocol for a randomised, controlled, non-inferiority trial","volume":"7","author":"Wang","year":"2017","journal-title":"BMJ Open"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000047346","article-title":"Platelet function and fibrinolytic agents: Two sides of a coin?","volume":"95","author":"Callahan","year":"2001","journal-title":"Cardiology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pep.2005.06.009","article-title":"Production and purification of Urokinase: A comprehensive review","volume":"45","author":"Bansal","year":"2005","journal-title":"Protein Expr. Purif."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S1474-4422(22)00171-5","article-title":"Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): A phase 2, randomised, open-label trial","volume":"21","author":"Bivard","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11239-021-02621-1","article-title":"Global coagulation assays in hypercoagulable states","volume":"54","author":"Lim","year":"2022","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"402","DOI":"10.5551\/jat.3673","article-title":"ARIC Study Inverstigators. Coagulation factors II, V, IX, X, XI, and XII, plasminogen, and alpha-2 antiplasmin and risk of coronary heart disease","volume":"17","author":"Yamagishi","year":"2010","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biologicals.2016.11.002","article-title":"A new manufacturing process to remove thrombogenic factors (II, VII, IX, X, and XI) from intravenous immunoglobulin gamma preparations","volume":"45","author":"Park","year":"2016","journal-title":"Biologicals"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1365-2141.1981.00627.x","article-title":"Coagulation abnormalities following intensive plasma exchange on the cell separator. II. Effects on factors I, II, V, VII, VIII, IX, X and antithrombin III","volume":"48","author":"Chirnside","year":"1981","journal-title":"Br. J. Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/ijlh.13932","article-title":"Neonatal haemostatic parameters in correlation to gestational age and birth weight","volume":"44","author":"Mitsiakos","year":"2022","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41573-020-0061-0","article-title":"Therapeutic strategies for thrombosis: New targets and approaches","volume":"19","author":"Mackman","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s12276-020-0401-5","article-title":"Protein disulfide isomerase in cardiovascular disease","volume":"52","author":"Xiong","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1161\/ATVBAHA.120.315754","article-title":"Thrombus Structural Composition in Cardiovascular Disease","volume":"41","author":"Alkarithi","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1161\/ATVBAHA.111.230631","article-title":"Fibrin clot structure and function: A role in the pathophysiology of arterial and venous thromboembolic diseases","volume":"31","author":"Undas","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/978-981-15-2517-9_4","article-title":"Antithrombotic Drugs-Pharmacology and Perspectives","volume":"1177","author":"Li","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.blre.2014.09.003","article-title":"Fibrinolysis and the control of blood coagulation","volume":"29","author":"Chapin","year":"2015","journal-title":"Blood Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"135","DOI":"10.5582\/ddt.2022.01040","article-title":"Proposal of an in vitro thrombus-growth model for evaluating anticoagulants","volume":"16","author":"Sawaguchi","year":"2022","journal-title":"Drug Discov. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1002\/cpz1.197","article-title":"Preparation and Mounting of Whole Blood Clot Samples for Mechanical Testing","volume":"1","author":"Sugerman","year":"2021","journal-title":"Curr. Protoc."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1073\/pnas.91.9.3670","article-title":"A faster-acting and more potent form of tissue plasminogen activator","volume":"91","author":"Keyt","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"109559","DOI":"10.1016\/j.exer.2023.109559","article-title":"Urokinase-type plasminogen activator promotes corneal epithelial migration and nerve regeneration","volume":"233","author":"Sugioka","year":"2023","journal-title":"Exp. Eye Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000527668","article-title":"Comparative Efficacy and Safety of Thrombolytic Agents for Pulmonary Embolism: A Bayesian Network Meta-Analysis","volume":"108","author":"Li","year":"2023","journal-title":"Pharmacology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3233\/CH-201049","article-title":"Safety aspect of intraoperative, local urokinase lysis in patients with acute lower limb ischemia","volume":"78","author":"Schierling","year":"2021","journal-title":"Clin. Hemorheol. Microcirc."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1161\/01.STR.7.2.143","article-title":"Intracranial bleeding associated with Urokinase therapy for acute ischemic hemispheral stroke","volume":"7","author":"Hanaway","year":"1976","journal-title":"Stroke"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ejvs.2022.11.010","article-title":"Collaborators. Major Bleeding during Thrombolytic Therapy for Acute Lower Limb Ischaemia: Value of Laboratory Tests for Clinical Decision Making, 17 Years of Experience","volume":"65","author":"Doelare","year":"2023","journal-title":"Eur. J. Vasc. Endovasc. Surg."}],"container-title":["Toxics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2305-6304\/12\/7\/458\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:04:13Z","timestamp":1760108653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2305-6304\/12\/7\/458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":44,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["toxics12070458"],"URL":"https:\/\/doi.org\/10.3390\/toxics12070458","relation":{},"ISSN":["2305-6304"],"issn-type":[{"value":"2305-6304","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]}}}